Volitionrx (VNRX) Research & Development (2011 - 2025)

Volitionrx's Research & Development history runs 11 years deep, the most recent figure standing at $2.5 million for Q4 2025.

• Quarterly Research & Development fell 4.37% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.8 million (down 26.92% YoY) and the FY2025 annual result came in at $10.1 million, down 29.99% from the prior year.
• Research & Development was $2.5 million for Q4 2025 at Volitionrx, up from $958567.0 in the prior quarter.
• Across five years, Research & Development topped out at $5.5 million in Q2 2023 and bottomed at -$8.2 million in Q4 2023.
• A 5-year average of $1.6 million and a median of $2.1 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2021 — Research & Development surged 1259.82% — and 2023, when it tumbled 297.68%.
• Volitionrx's Research & Development stood at -$6.0 million in 2021, then jumped by 168.85% to $4.1 million in 2022, then tumbled by 297.68% to -$8.2 million in 2023, then surged by 131.61% to $2.6 million in 2024, then declined by 4.37% to $2.5 million in 2025.
• Business Quant data shows VNRX's Research & Development at $2.5 million in Q4 2025, $958567.0 in Q3 2025, and $2.7 million in Q2 2025.